The thing is, a lot of retail morons (aka The Kramer and Cramer crowd), don't know how to look at the data and panic. Personally, I think the OS data which we have already seen (2 months survival +) is fine enough to show that the drug has a clinical benefit.
I'm sure there were a lot of morons out there that were expecting the data to show 12 months or something...which it probably will in the people it works best in (which is unfortunate they still don't have a proper biomarker for those patients)
News 
Market Data 
Discover 
